Aktienanalyse zu AbbVie Inc. (ABBV)ABBVAbbVie Inc.

AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, and Restasis. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its pipeline also includes zumilokibart and APG273. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

AbbVie Inc is a good buy right now, primarily driven by its current price of $276.47, which is below the raised analyst price targets of $315 and $305. The company has shown strong revenue growth, with a gross margin of 74.74% in Q2 2026, and a solid year-to-date price increase of 20.57%. However, a notable risk is its high forward P/E ratio of 16.39, indicating potential overvaluation if growth does not meet expectations.

20 analysts cover ABBV: 10 rate it Buy, 10 Hold and 0 Sell. The average price target is 252.00.